Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer
January 10 2020 - 6:30AM
- Dr. Harstrick, formerly Chief Medical Officer at Molecular
Partners and Senior Vice President Medical Sciences and Product
Lead for Erbitux® at ImClone Systems/Eli Lilly, will lead company’s
clinical development
Heidelberg, Germany, January 10, 2020 – Affimed
N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, today announced the appointment of Dr. Andreas Harstrick as
Chief Medical Officer, starting in March 2020. In this role, he
will oversee Affimed’s first-in-class innate cell engager clinical
programs and lead the Company’s efforts to advance clinical-stage
assets towards regulatory approvals.
“We are very excited to welcome Dr. Harstrick to
our team,” said Dr. Adi Hoess, Affimed’s CEO. “His demonstrated
track record of running successful clinical trials that have led to
regulatory approvals, deep oncology expertise, combined with his
proven ability to collaborate and lead large clinical organizations
will be invaluable as we continue to advance the development of our
first-in-class innate cell engager therapies.”
Dr. Harstrick brings to Affimed over 30 years of
extensive experience in cancer drug development, including
strategic leadership of three global phase 3 programs of new
biological entities that culminated in global regulatory approvals,
and multiple pivotal phase 3 studies. He has successfully designed
clinical trials that have led to approval of antibody drugs,
including Erbitux® (cetuximab) and Portrazza™ (necitumumab), both
which target the epidermal growth factor receptor (EGFR), and
Cyramza® (ramucirumab), a vascular endothelial growth factor
receptor 2 (VEGFR2) antagonist.
Most recently, Dr. Harstrick was the Chief
Medical Officer at Molecular Partners AG, where he oversaw
clinical activities, including expansion of the clinical team,
and was a member of the Management Board. At Molecular
Partners, he successfully transitioned several preclinical programs
to first-in-human studies. In addition, Dr. Harstrick has held
several senior executive roles, including Senior Vice President
Medical Sciences at ImClone Systems Inc., and following the
acquisition of ImClone Systems by Eli Lilly and Company, he served
as a member of the Lilly Oncology Program Review Board and Lilly
Oncology Business Unit Development Committee. Prior to ImClone and
Lilly, Dr. Harstrick was Senior Vice President Global Clinical
Development Unit Oncology at Merck Serono.
Dr. Harstrick, an oncologist by training, spent
his medical career at the University Hospital and Cancer Center
Hannover, Germany; the Roswell Park Cancer Institute, Buffalo NY;
as well as the West German Cancer Center, Essen, Germany. He earned
his MD at Medical School Hannover, Germany, and in 1999 he became
Associate Professor for Internal Medicine, University of Essen,
Germany.
Dr. Harstrick noted, “This is an exciting time
at Affimed with the registration-directed study underway for its
lead innate cell engager, AFM13, and the expected initiation of the
first-in-human study of AFM24, its EGFR- and CD16A-binding innate
cell engager, in the first quarter of 2020. I look forward to
working with the talented individuals at Affimed and bringing my
experience to drive these clinical programs to approval and make
these important therapies available to patients with limited
treatment options.”
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors. For
more information, please visit www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the value of our ROCK®
platform, our ongoing and planned preclinical development and
clinical trials, our collaborations and development of our products
in combination with other therapies, the timing of and our ability
to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates, our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, clinical trial data, our results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies, the industry in which
we operate, the trends that may affect the industry or us and the
risks, uncertainties and other factors described under the heading
“Risk Factors” in Affimed’s filings with the Securities and
Exchange Commission. Given these risks, uncertainties and other
factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future.
Affimed Investor and Media
Contact:
Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024